Lower dose chemoradiotherapy for elderly patients with HPV-associated oropharynx cancer
Official title: Pilot Feasibility Trial of Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly (DACHOC-E)
Run by Baptist MD Anderson Cancer Center, Florida · NCT06309225 · Data updated 2026-11-12
This study is testing a lower dose of radiation and chemotherapy to see if it can help older patients with HPV-related throat cancer while causing fewer side effects than the usual higher doses.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 65 Years to 99 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Baptist MD Anderson Cancer Center, Florida Academic / other |
| Drugs / interventions | immunotherapy, chemotherapy, radiation |
| Locations | 1 site (Jacksonville, Florida) |
| Status | Recruiting |
| Started | December 15, 2025 |
| Main results expected | September 30, 2027 |
| Study ends | September 30, 2027 |
| Registry record updated | September 29, 2026 |
| Trial ID | NCT06309225 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are elderly patients aged 65 and older with a confirmed diagnosis of squamous cell carcinoma of the oropharynx who are P16-positive and have measurable disease.
✕Probably not a fit
Patients with metastatic disease, recurrent cancer, or those who have received prior radiation therapy for other malignancies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effects of a modified regimen of lower dose radiation therapy and chemotherapy in elderly patients diagnosed with HPV-associated oropharynx cancer. Participants will receive radiation therapy once daily for five weeks, totaling 55 Gy, along with weekly cisplatin chemotherapy. The goal is to compare the outcomes of this less intensive treatment approach to standard higher dose regimens, focusing on both efficacy and side effects. By evaluating the results, researchers aim to determine if this new approach can maintain similar survival rates while reducing treatment-related complications.
Why it matters
Potential benefit: If successful, this study could lead to a safer treatment option for elderly patients with oropharynx cancer, minimizing side effects while maintaining effective cancer control.
How similar studies have gone: Previous studies have indicated that lower dose radiation can achieve comparable cancer control rates with fewer side effects, suggesting potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathologically proven diagnosis of squamous cell carcinoma of the oropharynx (tonsil, base of tongue, soft palate, or oropharyngeal walls) * Patients must have clinically or radiographically evident measurable disease at the primary site or at nodal stations. * P16-positive based on local site immunohistochemical tissue staining * Clinical stage T1-3, N1-2, M0 (AJCC, 8th ed.) * Age ≥ 65. * Normal organ and marrow function within 14 days prior to registration defined as follows: * Absolute neutrophil count ≥ 1,500/mcL * Platelets ≥ 100,000/mcL * Hemoglobin ≥ 8.0 g/dL * Total bilirubin ≤ 1.5× institutional upper limit of normal (ULN) * AST(SGOT) or ALT(SGPT) ≤ 3.0 × institutional ULN * Serum creatinine ≤ 1.5× ULN Exclusion Criteria: * Metastatic disease * Recurrent disease after primary management Cancers with center of mass is outside the oropharyngeal boundaries * Synchronous double primaries * Prior radiotherapy for lymphoma or other malignancy * Prior systemic therapy including immunotherapy * Severe active comorbidity where life expectancy is \<1 year. * Autoimmune disease * Uncontrolled HIV
Where it's running
-
Baptist MD Anderson Cancer Center
Jacksonville, Florida, United States Recruiting
Study contacts
- Study coordinator: Regulatory Office
- Email: RegBMDA@bmcjax.com
- Phone: 904-202-7300
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Postprandial drop and frailty in older adults having planned noncardiac surgery
This study tests whether a drop in blood pressure after meals and frailty predict low blood pressure after anesthesia starts in adults 65 and older undergoing planned noncardiac surgery.
-
Frailty Training for Emergency Nurses in Morocco
This trial tests whether a four-module training program helps Moroccan emergency nurses recognize and care for frail older adults in the ER.
-
Physical Function and Fall Risk in Older Adults in Lalín's Frailty Prevention Program
This study will look at how physical function and fall risk change in people 70 and older who participate in a routine frailty and falls prevention program, by comparing assessments before and after the 8–12 week program.
-
Home-based multicomponent exercise program for older adults with osteosarcopenia and frailty
This study tests a home-based exercise program built on the Fogg Behavior Model to see if it improves frailty, muscle strength, physical function, bone density, and quality of life in adults aged 60–85 with osteosarcopenia and frailty.
-
VIVI-OLIVE: Multicomponent Exercise and Olive Oil for Older Adults at High Risk of Falls
In adults 75 and older at high risk of falling, this study tests whether a 24-month plan of personalized exercise, Mediterranean diet guidance, and 60 mL of extra virgin olive oil daily can improve walking speed and reduce fall risk.
-
Frailty-focused prehabilitation before heart surgery
This study tests a home-based, frailty-tailored prehabilitation program for adults 65+ waiting 5 weeks or more for heart surgery to see if it improves fitness, frailty, heart-related function, nutrition, inflammation, quality of life, and hospital outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.